Novo Nordisk's H1 sales increased by 24% in Danish kroner
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Expect the international business including CDMO business to pick-up in the second half of the financial year
Shivani Satish Wagh takes on the role of Joint Managing Director
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated